











































The COVID-19 pandemic and the menstrual cycle: research gaps
and opportunities
Citation for published version:
Sharp, GC, Fraser, A, Sawyer, G, Kontourides, G, Easey, K, Ford, G, Olszewska, Z, Howe, L, Lawlor, D,
Alvergne, A & Maybin, JA 2021, 'The COVID-19 pandemic and the menstrual cycle: research gaps and
opportunities', International Journal of Epidemiology. https://doi.org/10.1093/ije/dyab239
Digital Object Identifier (DOI):
10.1093/ije/dyab239
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
International Journal of Epidemiology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 22. Dec. 2021
Opinion
The COVID-19 pandemic and the menstrual
cycle: research gaps and opportunities
Gemma C Sharp ,1,2* Abigail Fraser ,1,2,3 Gemma Sawyer,1
Gabriella Kountourides,4 Kayleigh E Easey ,1,2 Gemma Ford,5
Zuzanna Olszewska,4 Laura D Howe,1,2 Deborah A Lawlor,1,2,3
Alexandra Alvergne4,6 and Jacqueline A Maybin 7
1Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK, 2MRC
Integrative Epidemiology Unit, University of Bristol, Bristol, UK, 3NIHR Bristol Biomedical Research
Centre, Bristol, UK, 4School of Anthropology, University of Oxford, Oxford, UK, 5Translational Health
Sciences, Bristol Medical School, University of Bristol, Bristol, UK, 6Institut des Sciences de
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Menstrual cycle features and the COVID-19
pandemic
Over 50% of the global population will experience men-
struation, and menstrual disorders are extremely common
and debilitating.1 Problematic menstruation may cause
anaemia,2 has a significant negative impact on quality of
life and is a huge socioeconomic burden for women, their
families, health services and society.3–7 Standardized
parameters for typical menstruation have been defined by
the International Federation of Gynecology and Obstetrics
(FIGO) regarding menstrual frequency, duration, regular-
ity and volume, and deviation from these may constitute
abnormal uterine bleeding.8 Features of the menstrual cy-
cle are also increasingly being recognized as ‘vital signs’—
acting as both indicators and possible determinants of
broader health and well-being.9 For example: irregular and
long menstrual cycles have been associated with a greater
risk of premature mortality,10 and infrequent or absent
menstruation can be an indicator of reduced fertility,3
which itself can be associated with a number of chronic
conditions.11 Since the beginning of the COVID-19
pandemic, there have been accumulating discussions on so-
cial media and blogs indicating that women have experi-
enced menstrual changes, including altered menstrual
duration, frequency, regularity, and volume (heavier bleed-
ing and clotting), increased dysmenorrhoea and worsened
premenstrual syndrome (PMS) (e.g. Morgan 202112).
More recent anecdotal reports of menstrual changes after
vaccination for COVID-19 have fuelled vaccine hesitancy
or refusal. There is an important public health imperative
for accurate scientific investigation of these phenomena.
Unfortunately, questions about menstruation have been
excluded from most large-scale COVID-19 studies (includ-
ing vaccine trials), so it is currently unclear how many
women have experienced menstrual cycle changes, how
long these changes persisted, whether menstrual changes
reflect common and expected fluctuation in menstrual fea-
tures over time or the impact of an exposure (e.g. pan-
demic restrictions, infection/illness, treatment, vaccine)
and what exactly this exposure is. Given this complexity,
the impact of any menstrual changes since the start of the
pandemic is also unclear. Even outside the context of
COVID-19, studying menstrual cycle features is
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challenging. Normal variation exists within women over
the lifespan and between women in relation to characteris-
tics such as history of infertility, parity, body mass index
(BMI) and exercise.13 In addition, menstrual cycle features
such as volume, pain and PMS symptoms are subjective
and data are necessarily collected, in health care as well as
research, by self-report.
In this paper, we aimed to identify and evaluate the
existing scientific literature on menstrual cycle feature
changes in the COVID-19 pandemic and provide sugges-
tions for future research. Using a pre-specified search pro-
tocol (available at [https://osf.io/xg3mw/], developed in
accordance with PRISMA guidelines14) we searched
PubMed, Scopus and preprint servers (BioRxiv and
MedRxiv) across all fields for terms related to menstrua-
tion AND COVID-19 (full review methods in the
Supplementary Methods, available as Supplementary data
at IJE online). The review process is summarized in
Figure 1. We identified 12 small studies reporting on men-
strual cycle features during the pandemic, either in relation
to the COVID-19 pandemic period (Table 1; 15–23) or
COVID-19 illness specifically (Table 2; 24–26) All studies
are summarized in more detail in Supplementary Table S1,
available as Supplementary data at IJE online. Articles
were included if they described features of the menstrual
cycle (e.g. cycle length, regularity, heaviness, pain, PMS
symptoms) before and during, or over the course of, the
COVID-19 pandemic. The final search was performed on
31 August 2021.
Possible causal explanations
The menstrual cycle is regulated by a complex interplay of
hormones that interact with the immune, vascular and co-
agulation systems, and these interactions can influence
menstrual bleeding and severity of (pre)menstrual symp-
toms.28 These changes will occur following effects on
hypothalamic-pituitary-ovarian-endometrial function
(Figure 2). In the context of the COVID-19 pandemic, it is
plausible that such effects could be instigated by one or
more of the following exposures.
COVID-19 mitigation and control strategies
COVID-19 mitigation and control strategies, like lock-
downs and social distancing, have led to increases in psy-
chological stress, depression and anxiety and reductions in
general well-being, particularly in young adults and
Figure 1 A flowchart of articles identified and filtered through our systematic review protocol
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women.33 Studies have also identified associations between
the pandemic and weight gain and changes in health
behaviours.34 Psychological stress is a known risk factor
for hypothalamic hypogonadism, resulting in infrequent or
absent menstruation.35 There is also a well-known link be-
tween changes in weight and the menstrual cycle, and
some (inconclusive) evidence that the menstrual cycle can
be altered by health behaviours such as changes in alcohol
consumption, diet and physical activity.36
The studies in Table 1 consider menstrual cycle feature
changes in relation to the pandemic period. Their results
could therefore reflect effects of pandemic mitigation and
control strategies (assuming they are not explained by con-
founding or other types of bias).
SARS-CoV-2 infection and COVID-19 illness
SARS-CoV-2 infection and COVID-19 illness could affect
the hypothalamic-pituitary-ovarian-endometrial axis with
resulting changes to the menstrual cycle. Hypothalamic
hypogonadism may occur in the presence of any severe ill-
ness, including COVID-19, and result in temporary ame-
norrhoea or infrequent menses. This protective mechanism
enables diversion of energy resources from reproduction to
Table 1 A summary of studies comparing menstrual cycle features during and before the COVID-19 pandemic (see
Supplementary Table S1, available as Supplementary data at IJE online for more information)
Table 2 A summary of studies comparing menstrual cycle features in COVID-19 cases or controls, or before vs during illness











/ije/advance-article/doi/10.1093/ije/dyab239/6447179 by guest on 03 D
ecem
ber 2021
the immune response.37 This may also explain why those
experiencing long-term symptoms of Ebola infection (Post
Ebola Syndrome; possibly analogous to Long Covid) have
reported menstrual cessation or irregularity.38
Alternatively, or additionally, there may be more spe-
cific interactions between the reproductive system and
SARS-CoV-2 infection. This may occur at the ovarian/en-
dometrial level. The ovarian hormone progesterone is pre-
dominantly anti-inflammatory.39 Progesterone levels fall
dramatically before menstruation, with a resulting influx
of inflammatory cells to the local endometrial environment
that ultimately leads to the shedding of the functional en-
dometrium at menstruation.40 Intense vasoconstriction of
the specialized endometrial spiral arterioles and activation
of the local coagulation system act to limit menstrual blood
loss. It is proposed that ACE2 receptors are present on
ovarian and endometrial tissue41,42 and hence SARS-CoV-
2 infection may hypothetically affect ovarian hormone
production and/or the endometrial response at menses. For
example, altered endometrial leukocyte number/phenotype
during or following SARS-CoV-2 infection has the poten-
tial to impact on menstrual blood loss. Previous research
has shown that viral infection-induced immune disruption
was associated with exacerbation of progesterone-related
premenstrual symptoms.43 Furthermore, COVID-19 has
also been associated with endothelial cell dysfunction and
alterations in the coagulation system, both critical compo-
nents of endometrial function at menstruation, indicating a
potential endometrial mechanism for menstrual
disturbance.40,44
Reciprocally, reproductive hormones and/or menstrua-
tion may also affect the severity of COVID-19, i.e. varia-
tion in severity of symptoms of COVID-19 across different
stages of the menstrual cycle.45 In a recent study of Long
COVID symptoms by Davis et al.27 (identified through our
review and summarized in Table 2), over a third of partici-
pants experienced relapses of symptoms during or before
menstruation, i.e. during the most inflammatory phases of
the cycle. Cyclical variation in symptoms has also been
documented in those with myalgic encephalomyelitis/
chronic fatigue syndrome (ME/CFS), a chronic condition
often triggered by infection, which has been compared
with Long Covid. Female ME/CFS patients often notice
flare-ups of their symptoms during the premenstrual phase
of their cycles or at the onset of menopause.46
The three studies in Table 2 consider menstrual cycle
feature changes in relation to COVID-19 illness.
COVID-19 treatments
COVID-19 treatments that have been advised for COVID-
19 symptoms include antipyretics and analgesics, such as
Figure 2 How the pandemic mitigation/control factors and COVID-19 illness, treatment and vaccines may impact on the hypothalamic-pituitary-ovar-
ian-endometrial axis to alter menstrual frequency, duration, regularity and/or volume29–32
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paracetamol, aspirin and other non-steroidal anti-inflam-
matories (NSAIDs). NSAIDs affect prostaglandin synthesis
and endometrial prostaglandin levels, and via these mecha-
nisms can reduce menstrual pain and blood loss.47,48
Although some observational studies suggest aspirin may
alter blood loss, randomized controlled trials suggest this is
not the case, though it does reduce pain associated with
menstruation.48,49 For hospitalized COVID-19 patients,
one of the earliest identified effective treatments was dexa-
methasone which may affect menstrual cycle patterns and
blood loss through cortisol actions.50 The impact of novel
(as opposed to repurposed) treatments, including the new
monoclonal antibodies, is unknown, though anti-tumour
necrosis factor (TNF) monoclonal antibodies have some
impact on the endometrium in non-human primate stud-
ies.51 In addition, some treatments might cancel out cycle
changes; for example, low oxygen saturation has been
linked to low-grade inflammation and anovulatory
cycles,52 but the possibility that mechanical ventilation
might impact on cycles has not been explored.
We did not identify any studies of menstrual cycle fea-
ture changes in relation to COVID-19 treatments.
COVID-19 vaccines
COVID-19 vaccines have been reported in the media and
via government monitoring systems as causing changes in
menstrual features (for example, as of early September
2021, more than 30 000 reports had been made to the UK
Medicines and Healthcare Products Regulatory Agency’s
yellow card surveillance scheme53). However, we did not
identify any studies that explored this. Previous research
on HPV and flu vaccinations have shown these can be as-
sociated with changes in menstrual cycle features.54,55 In a
study of 30 000 Japanese women, receiving an HPV vac-
cine was associated with increased age-adjusted odds of
hospital visits for ‘abnormal amount of menstrual bleed-
ing’ [odds ratio (OR): 1.43, 95% confidence interval (CI):
1.13–1.82], ‘irregular menstruation’ (OR: 1.29, 95% CI:
1.12–1.49) and chronic, persisting ‘abnormal amount of
menstrual bleeding’ (OR: 1.41, 95% CI: 1.11–1.79).54 In
addition, a clinical study found that women had lower lev-
els of post-ovulation progesterone following inactivated in-
fluenza vaccination.55 These studies suggest that there is an
impact of vaccination (in general) on menstrual symptoms.
Given the widespread use of vaccinations, we expect any
effects to be transient. The mechanism by which vaccine
effects on menstrual cycle features occur remains under -
researched and undetermined.
Potential research bias
In addition to true causal effects, it is also possible that ob-
served associations between the COVID-19 pandemic and
menstrual cycles could be explained by various types of
bias. These include reporting bias introduced by height-
ened health awareness, stemming from people monitoring
their own health more closely during the pandemic/illness
and consequently being more likely to notice menstrual cy-
cle features and report (apparent) changes compared with
pre-pandemic/illness. This type of bias is possible even in
hospital-based studies for some menstrual cycle features,
like pain and PMS, which are measured subjectively. Many
of the studies we identified relied on self-reported, often
retrospective or cross-sectional data.
Studies have also relied on small, selected samples,
meaning their findings may not be generalizable to other
populations (i.e. lacking external validity) and are highly
susceptible to selection bias, which could bias estimates
(i.e. lacking internal validity). For example, online surveys
select for internet users and are more likely to be com-
pleted by and shared among people affected by the condi-
tion being studied. This may result in biased estimates as
well as limit the generalizability of findings to larger
populations.
Furthermore, because of confounding, some studies are
unable to distinguish between the various pandemic-
related exposures (i.e. mitigation/control strategies, infec-
tion/illness, treatments, vaccines). In studies of the effect of
COVID-19 illness on menstrual cycle features, another
source of confounding could be hormonal contraceptive
use, which is highly prevalent among women of reproduc-
tive age. Depending on the type of contraceptive, hormonal
contraceptive use alters hormonal cyclicity, which can in-
fluence both menstrual cycle features and immune cyclic-
ity, and therefore could potentially affect COVID-19
symptom severity. Some authors have claimed that estra-
diol, a component of the combined hormonal contracep-
tive pill, offers a protective effect against COVID-19
severity and mortality,56 and a study using data from the
COVID Symptom Tracker App reported that women aged
18–45 taking the combined oral contraceptive pill had
lower rates of predicted COVID-19 and lower hospital at-
tendance than women taking no form of hormone ther-
apy57 (although the role of residual confounding, most
notably by age, cannot be ruled out). Hormonal contracep-
tive use might also be an effect modifier, for example
pandemic-related exposures might affect features of
contraceptive-controlled menstrual cycles differently from
those of natural cycles. Thus, the relationship between
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COVID-19 severity and features of the menstrual cycle be-
tween hormonal contraceptive users and non-users, as well
as between users taking progesterone only and combined
hormonal contraceptives, merits further investigation.
Four of the 12 studies in Tables 1 and 2 either stratified by
hormonal contraceptive use or excluded users, four studies
just described use within the sample and four did not men-
tion it at all.
Finally, only one of the studies included here used a rec-
ognized questionnaire to measure menstrual cycle features
(Freitas et al.20 used the Premenstrual Symptoms Screening
Tool, PSST58) and no studies made full use of the globally
agreed International Federation of Gynecology and
Obstetrics (FIGO) standardized parameters for menstrual
frequency, duration, regularity and volume.8 Using stan-
dardized parameters is important for the generation of ro-
bust, comparable research data, and for assessing whether
menstrual changes deviate from what would be considered
normal and expected variation in physiological menstrua-
tion. As has been highlighted in the COVID-19 research
more widely, there is also a need to use common defini-
tions of COVID-19 and Long Covid.59 Adherence to such
recommendations during study design will increase consis-
tency and facilitate the interpretation of results to drive
clinical and societal impact.
The need for further research
Although new research is continuously being published on
COVID-19, the lack of high-quality research focusing on
COVID-19 and the menstrual cycle mirrors the broader fo-
cus of medical research, which does not prioritize women’s
health, particularly outside the context of pregnancy. The
finding that menstrual cycles appear to have been affected
by the COVID-19 pandemic could have important implica-
tions for society, gender-based inequalities and the post-
COVID economic recovery. Women are more likely than
men to have significant childcare responsibilities and inse-
cure employment and finances,60 and therefore are dispro-
portionately affected by the COVID-19 pandemic60; 26%
of the global population are women of reproductive age
and the vast majority menstruate. This population is also
of working age and/or in education. In addition to affect-
ing women’s physical health, mental well-being and quality
of life,9 menstruation-related symptoms are an important
source of economic burden, through decreased productiv-
ity and increased absence from the workplace 61 and
school.62 Exacerbation of menstrual symptoms during the
pandemic may be further compounded by pandemic-
related issues with living arrangements and privacy, access
to and affordability of menstrual products and reduced
availability and accessibility of sexual and reproductive
health care services.63 Therefore, as the world continues to
cope with and begins to recover from the COVID-19 pan-
demic, there is a need for further research to help under-
stand and mitigate the impacts of the pandemic on
menstrual health, which could help to minimize gender-
based health and social inequalities. The pandemic has also
highlighted the need for more research to inform a broader
understanding of how external, environmental factors can
influence the menstrual cycle, and how the menstrual cycle
can interact with other aspects of health in a bidirectional
manner.
Outstanding research questions and
considerations
In Table 3 we provide a list of outstanding questions that
could be applied to studies of any menstrual cycle feature.
Studies that minimize selection and reporting bias, con-
trol for key confounders (selected depending on the expo-
sure and outcome of interest), and use harmonized or
standardized definitions of menstrual cycle features and
COVID-19/Long Covid, are needed. Researchers will need
to consider whether they can feasibly disentangle and iden-
tify effects of the various exposures (pandemic mitigation/
control factors, acute COVID-19, Long Covid, treatments,
vaccines) for a growing proportion of the population who
have been exposed to most or all of them. To be most in-
formative for the global population of women and people
who menstruate, future research should continue to focus
on populations from a variety of countries and settings.
Nine of the 12 studies in Tables 1 and 2 were conducted
on populations from low- or middle-income countries
(Brazil, China, Indonesia, Jordan and Turkey) and three
were open to people from any country (although we note
that high-income countries were over-represented). For
their target populations, future studies should consider and
adequately describe the situation with the pandemic (for
example, which restrictions were in place, for how long,
how they were enforced, general compliance etc.), social
attitudes to menstruation, awareness of menstrual health
and availability and accessibility of menstrual products
and health services. These factors provide much needed so-
cial context to enable findings to be interpreted and com-
pared across populations.
An ideal study would have prospective, repeat longitu-
dinal data on menstrual cycle patterns and symptoms, in
addition to repeat data on exposures related to pandemic
mitigation and control, COVID-19 (SARs-Cov-2 infection,
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acute symptoms and symptoms of Long-Covid), treatments
and vaccination. Setting up such a study this long after the
start of the pandemic would not be ideal. However, it is
possible that existing research cohorts or digital fitness
trackers and menstrual cycle tracking smartphone apps
may have already collected some of these repeat measures.
Each of these methods has its own strengths and limita-
tions. For example, data from smartphone menstrual cycle
tracker apps are collected frequently and longitudinally on
large numbers of women, but the data are affected by a
high degree of missingness, and collected from a select
group of smartphone users, many of whom are using the
Table 3 Outstanding questions about the relationship between the COVID-19 pandemic and menstrual cycle features
Area of study Specific questions
The prevalence and characteristics of women experiencing menstrual
cycle feature changes during the COVID-19 pandemic
What proportion of women have experienced changes to their men-
strual cycle features during the pandemic? Which features were af-
fected? To what extent? Does the association vary by
demographic factors like age, parity, ethnicity and socioeconomic
position? Is it influenced by any other factors, like hormonal con-
traceptive use?
The effect of pandemic mitigation and control strategies on men-
strual cycle features
Which pandemic-related stressors and behaviour changes are associ-
ated with changes to menstrual cycle features? What are the un-
derlying biological mechanisms? How persistent are these effects;
how long do menstrual cycle changes take to revert to normal?
Can behaviour-related or stress-relieving interventions help to reg-
ulate menstrual changes?
The effect of COVID-19 illness on menstrual cycle features Is the severity of COVID-19 and the types of other symptoms experi-
enced associated with variation in changes in menstrual cycle fea-
tures? What biological mechanisms explain this effect?
The effect of COVID-19 treatments on menstrual cycle features How do COVID-19 treatments affect menstrual cycle features? Does
timing or type of treatment make a difference? Does menstrual cy-
cle stage affect treatment efficacy or side effects?
The effect of COVID-19 vaccines on features of the menstrual cycle How do COVID-19 vaccines affect menstrual cycle features? Does
timing or type of vaccine make a difference? Does menstrual cycle
stage affect vaccine efficacy or side effects?
The long term or latent effect of any pandemic-related exposure
(mitigation/control strategies, COVID-19 illness, treatment and
vaccines) on reproductive health
Do these exposures affect timing of menarche (if prepubertal chil-
dren are exposed) or the menopause? Are there effects on fertility
(both achieving and maintaining a pregnancy)? How? What are
the best strategies to mitigate any negative effects?
Factors that could modify effects of these pandemic exposures on
menstrual health
How have affected people dealt with changes to their menstrual cy-
cle features? Which self-care approaches have they used and how
effective have these been? Have people experienced difficulties
accessing support from health care providers? Have they had diffi-
culty accessing menstrual products? (There have already been
some studies on this.63) Which groups have been most affected?
What are the most effective management strategies for health care
providers to follow during a pandemic?
Reverse effects: the effect of menstrual cycle stage on COVID-19
and Long Covid symptoms
Are women more susceptible to coronavirus infection, or at higher
risk of experiencing severe symptoms, at certain stages of the men-
strual cycle (e.g. during the perimenstrual phase, when ovarian
hormone levels are transiently but significantly decreased)? What
are the underlying biological mechanisms? Do type and severity of
acute COVID-19 or Long Covid symptoms show variation over
the menstrual cycle? Does the menstrual cycle and/or female re-
productive hormones explain the higher incidence of Long Covid
in working-age women than in men? Does hormonal therapy or
contraception affect symptoms? Does cycle stage influence the ac-
curacy of COVID-19 tests? If Long Covid symptoms indeed fluc-
tuate according to the menstrual cycle, what can this suggest
about the pathophysiology of Long Covid itself?
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app to track fertility while trying to get pregnant.
Collecting relevant data on menstrual cycle changes within
existing cohort studies also enables longitudinal collection
of data and missingness may be lower (and potential selec-
tion bias can be investigated with existing data), but fre-
quency of repeat data collection and sample sizes are likely
to be smaller than datasets collected from smartphone
apps. Cautious interpretations from individual studies will
be necessary. More conclusive inferences about the direc-
tion of any causal effect may be possible by triangulating
evidence garnered using several different approaches with
different and unrelated key sources of bias.64 An interna-
tional research network could help address several of the
research questions in Table 3. For example, any studies
with repeat measures that could separate different expo-
sures could be pooled to increase statistical power.
Exploring heterogeneity between studies would help un-
derstanding of how context might moderate any effect of
the various exposures, and could also help with under-
standing the extent to which results might be biased. We
would urge anyone with such data to contact the authors
to discuss the possibility of establishing such a network.
Conclusion
Anecdotal evidence discussed online, government monitor-
ing systems, and a small number of scientific studies of var-
iable quality suggest that many women have experienced
changes to features of their menstrual cycle during the
COVID-19 pandemic, either due to pandemic-related fac-
tors like stress and behaviour changes and/or due to
COVID-19 illness itself. Further research into the effects of
COVID-19 and other health-related exposures on women’s
menstrual health is urgently needed. Without robust men-
strual data collection and analysis, menstrual problems
will continue to be occult and under-managed in society.
Determining the scale of menstrual problems, their cause
and the impact on those who menstruate and wider society
will allow identification of new preventative and therapeu-
tic strategies. Findings can inform policies to mitigate
against gender inequalities in health and society, allowing
us to ‘build back better’ post-COVID.
Supplementary Data
Supplementary data are available at IJE online.
Funding
G.C.S., K.E., L.D.H., A.F. and D.A.L. work in the UK Medical
Research Council Integrative Epidemiology Unit at the University of
Bristol (MC_UU_00011/5 and MC_UU_00011/6), and A.F. and
D.A.L. also work in the Bristol National Institute for Health
Research (NIHR) Biomedical Research Centre. D.A.L. is a British
Heart Foundation Chair (CH/F/20/90003) and NIHR Senior
Investigator (NF-0616–10102). G.C.S. is financially supported by
the Medical Research Council (New Investigator Research Grant,
MR/S009310/1) and the European Joint Programming Initiative ‘A
Healthy Diet for a Healthy Life’ (JPI HDHL, NutriPROGRAM
project, UK MRC MR/S036520/1). J.M. is funded by a Wellcome
Trust Fellowship (209589/Z/17/Z), RSE grant (1007), Tenovus
Scotland and centre grants (G1002033 and MR/N022556/1). The
funders had no role in designing this research.
Author Contributions
G.C.S.: conceptualiation, manuscript writing. G.S., G.K.,
K.E., Z.O., G.F., J.M., A.A., L.D.H., A.F., D.A.L.: manu-




1. Royal College of Obstetricians and Gynaecologists. National
Heavy Menstrual Bleeding Audit. 2014. https://www.rcog.org.
uk/globalassets/documents/guidelines/research--audit/national_
hmb_audit_final_report_july_2014.pdf (12 November 2021,
date last accessed).
2. Nelson AL, Ritchie JJ. Severe anemia from heavy menstrual
bleeding requires heightened attention. Am J Obstet Gynecol
2015;213:97.e1–e6.
3. Shufelt C, Torbati T, Dutra E. Hypothalamic amenorrhea and
the long-term health consequences. Semin Reprod Med 2017;35:
256–62.
4. Banikarim C, Chacko MR, Kelder SH. Prevalence and impact of
dysmenorrhea on Hispanic female adolescents. Arch Pediatr
Adolesc Med 2000;154:1226.
5. Dennerstein L, Lehert P, Heinemann K. Epidemiology of pre-
menstrual symptoms and disorders. Menopause Int 2012;18:
48–51.
6. Prentice A. Health care implications of dysfunctional uterine
bleeding. Baillieres Best Pract Res Clin Obstet Gynaecol 1999;
13:181–88.
7. Frick KD, Clark MA, Steinwachs DM et al.; STOP-DUB
Research Group. Financial and quality-of-life burden of dysfunc-
tional uterine bleeding among women agreeing to obtain surgical
treatment. Womens Health Issues 2009;19:70–78.
8. Munro MG. Practical aspects of the two FIGO systems for man-
agement of abnormal uterine bleeding in the reproductive years.
Best Pract Res Clin Obstet Gynaecol 2017;40:3–22.
9. ACOG Committee. Opinion No. 651: Menstruation in girls and
adolescents: using the menstrual cycle as a vital sign. Obstet
Gynecol 2015;126:e143–46.
10. Wang Y-X, Arvizu M, Rich-Edwards JW et al. Menstrual cycle
regularity and length across the reproductive lifespan and risk of
premature mortality: prospective cohort study. BMJ 2020;371:
m3464.






/ije/advance-article/doi/10.1093/ije/dyab239/6447179 by guest on 03 D
ecem
ber 2021
11. Hanson B, Johnstone E, Dorais J, Silver B, Peterson CM,
Hotaling J. Female infertility, infertility-associated diagnoses,
and comorbidities: a review. J Assist Reprod Genet 2017;34:
167–77.
12. Morgan EP. Periods: why women’s menstrual cycles have gone
haywire. The Guardian, 25 March 2021.
13. Jukic AMZ, Weinberg CR, Wilcox AJ, McConnaughey DR,
Hornsby P, Baird DD. Accuracy of reporting of menstrual cycle
length. Am J Epidemiol 2008;167:25–33.
14. Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020
statement: an updated guideline for reporting systematic reviews.
BMJ 2021;372:n71.
15. Yuksel B, Ozgor F. Effect of the COVID-19 pandemic on female
sexual behavior. Int J Gynaecol Obstet 2020;150:98–102.
16. Aolymat IA. Cross-sectional study of the impact of COVID-19
on domestic violence, menstruation, genital tract health, and
contraception use among women in Jordan. Am J Trop Med Hyg
2020;519–25.
17. Bruinvels G, Goldsmith E, Blagrove RC, Martin D, Shaw L,
Piasecki J. How lifestyle changes within the COVID-19 global
pandemic have affected the pattern and symptoms of the men-
strual cycle. MedRxiv 3 Feb 2021. doi: 10.1101/
2021.02.01.21250919. Preprint: not peer reviewed.
18. Phelan N, Behan LA, Owens L. The impact of the COVID-19
pandemic on women’s reproductive health.. Front Endocrinol
2021;12:642755.
19. Demir O, Sal H, Comba C. Triangle of COVID, anxiety and
menstrual cycle. J Obstet Gynaecol 2021;1257–61.
20. Freitas FDF, Medeiros Acq D, Lopes FDA. Effects of social dis-
tancing during the COVID-19 pandemic on anxiety and eating
behavior—a longitudinal study. Front Psychol 2021;12:645754.
21. Takmaz T, Gundogmus I, Okten SB, Gunduz A. The impact of
COVID-19-related mental health issues on menstrual cycle charac-
teristics of female healthcare providers. J Obstet Gynaecol Res 2021;
3241–49.
22. Prabowo KA, Ellenzy G, Wijaya MC, Kloping YP. Impact of
work from home policy during the COVID-19 pandemic on
mental health and reproductive health of women in Indonesia.
Int J Sex Health 2021;https://www.tandfonline.com/doi/full/
10.1080/19317611.2021.1928808.
23. Ramos-Echevarrı́a PM, Soto-Soto Dm Torres-Reverón A et al.
Impact of the early COVID 19 era on endometriosis patients:
symptoms, stress and access to care. J Endometr Pelvic Pain
Disord 2021;111–21.
24. Li K, Chen G, Hou H et al. Analysis of sex hormones and men-
struation in COVID-19 women of child-bearing age. Reprod
Biomed Online 2021;42:260–67.
25. Davis HE, Assaf GS, McCorkell L et al. Characterizing long COVID
in an International Cohort: 7 months of symptoms and their impact.
medRxiv 27 Dec 2020. doi: 10.1101/2020.12.24.20248802,.
Preprint: not peer reviewed
26. Ding T, Wang T, Zhang J et al. Analysis of ovarian injury associ-
ated with COVID-19 disease in reproductive-aged women in
Wuhan, China: an observational study. Front Med 2021;8:
635255.
27. Davis HE, Assaf GS, McCorkell L et al. Characterizing long
COVID in an international cohort: 7 months of symptoms and
their impact. EClinicalMedicine 2021;38:101019.
28. Bertone-Johnson ER, Ronnenberg AG, Houghton SC et al.
Association of inflammation markers with menstrual symptom
severity and premenstrual syndrome in young women. Hum
Reprod 2014;29:1987–94.
29. Rae M, Mohamad A, Price D et al. Cortisol inactivation by 11b-
hydroxysteroid dehydrogenase-2 may enhance endometrial an-
giogenesis via reduced thrombospondin-1 in heavy menstrua-
tion. J Clin Endocrinol Metab 2009;94:1443–50.
30. Davies J, Kadir RA. Endometrial haemostasis and menstruation.
Rev Endocr Metab Disord 2012;13:289–99.
31. Maybin JA, Murray AA, Saunders PTK, Hirani N, Carmeliet P,
Critchley HOD. Hypoxia and hypoxia inducible factor-1a are
required for normal endometrial repair during menstruation.
Nat Commun 2018;9:295.
32. Malik S, Day K, Perrault I, Charnock-Jones DS, Smith SK.
Reduced levels of VEGF-A and MMP-2 and MMP-9 activity and
increased TNF-a in menstrual endometrium and effluent in
women with menorrhagia. Hum Reprod 2006;21:2158–66.
33. Kwong ASF, Pearson RM, Adams MJ et al. Mental health before
and during the COVID-19 pandemic in two longitudinal UK
population cohorts. Br J Psychiatry 2020;1–10.
34. Robinson E, Boyland E, Chisholm A et al. Obesity, eating behav-
ior and physical activity during COVID-19 lockdown: a study of
UK adults. Appetite 2021;156:104853.
35. Nagma S, Kapoor G, Bharti R et al. To evaluate the effect of per-
ceived stress on menstrual function. J Clin Diagn Res 2015;9:
QC01–03.
36. Hahn KA, Wise LA, Riis AH et al. Correlates of menstrual cycle
characteristics among nulliparous Danish women. Clin
Epidemiol 2013;5:311–19.
37. McDade TW. The ecologies of human immune function. Annu
Rev Anthropol 2005;34:495–521.
38. Wilson HW, Amo-Addae M, Kenu E, Ilesanmi OS, Ameme DK,
Sackey SO. Post-Ebola Syndrome among Ebola virus disease sur-
vivors in Montserrado County, Liberia 2016. BioMed Res Int
2018;2018:1909410–18.
39. Hughes GC. Progesterone and autoimmune disease. Autoimmun
Rev 2012;11:A502–14.
40. Maybin JA, Critchley HOD. Menstrual physiology: implications
for endometrial pathology and beyond. Hum Reprod Update
2015;21:748–61.
41. Chadchan SB, Popli P, Maurya VK, Kommagani R. The SARS-
CoV-2 receptor, Angiotensin converting enzyme 2 (ACE2) is re-
quired for human endometrial stromal cell decidualization. Biol
Reprod 2020;336–43.
42. Kong S, Yan Z, Yuan P et al. Comprehensive evaluation of
ACE2 expression in female ovary by single-cell RNA-seq analy-
sis. BioRxiv 23 Feb 2021. doi: 10.1101/2021.02.23.432460.
Preprint: not peer reviewed.
43. Alvergne A, Vlajic Wheeler M, Högqvist Tabor V. Do sexually
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